Robert Bok, MD, PhD
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Robert Bok, MD, PhD sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
Robert Bok, MD, PhD: 3 sponsored US clinical trials, 3 recruiting.
Robert Bok, MD, PhD sponsors 3 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Adult Gliomas, Mixed, with 1 trials.
Upper-quartile sponsor footprint
Robert Bok, MD, PhD sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
3 total, page 1 of 1
Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer
NCT06391034
Hyperpolarized Carbon-13 Alpha-ketoglutarate Imaging in IDH Mutant Glioma
NCT05851378
Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors
NCT05599048
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
Therapeutic Areas
What is open in the Robert Bok, MD, PhD pipeline
3 recruiting of 3 indexed (100% open).
Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: Adult Gliomas, Mixed (1 trial), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Robert Bok, MD, PhD: open-pipeline peers nationwide
Peers matched on 3 registered trials and 100% open enrollment, not the therapeutic-area sidebar.
Robert Bok, MD, PhD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 trials (± recruiting share)
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors near 100% open enrollment (± trial volume)
- AAVantgarde Bio Srl · 100% recruiting · 2 trials
- Acorn Biolabs · 100% recruiting · 3 trials
- Acrivon Therapeutics · 100% recruiting · 2 trials
- ADARx Pharmaceuticals · 100% recruiting · 4 trials
Related
What to do with this Robert Bok, MD, PhD page
3 registered trials is a research-attention snapshot, not an endorsement of Robert Bok, MD, PhD or any single study.
- 3 of Robert Bok, MD, PhD's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Adult Gliomas, Mixed is the condition Robert Bok, MD, PhD studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Adult Gliomas, Mixed trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Robert Bok, MD, PhD pipeline card: 3 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.